Ventyx Biosciences (VTYX) Competitors $2.08 +0.04 (+1.96%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$2.16 +0.08 (+3.80%) As of 07:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTYX vs. ANAB, IMTX, TRVI, NUVB, DAWN, GHRS, STOK, SANA, MRVI, and URGNShould you be buying Ventyx Biosciences stock or one of its competitors? The main competitors of Ventyx Biosciences include AnaptysBio (ANAB), Immatics (IMTX), Trevi Therapeutics (TRVI), Nuvation Bio (NUVB), Day One Biopharmaceuticals (DAWN), GH Research (GHRS), Stoke Therapeutics (STOK), Sana Biotechnology (SANA), Maravai LifeSciences (MRVI), and Urogen Pharma (URGN). These companies are all part of the "pharmaceutical products" industry. Ventyx Biosciences vs. Its Competitors AnaptysBio Immatics Trevi Therapeutics Nuvation Bio Day One Biopharmaceuticals GH Research Stoke Therapeutics Sana Biotechnology Maravai LifeSciences Urogen Pharma AnaptysBio (NASDAQ:ANAB) and Ventyx Biosciences (NASDAQ:VTYX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk. Do institutionals and insiders hold more shares of ANAB or VTYX? 97.9% of Ventyx Biosciences shares are owned by institutional investors. 33.5% of AnaptysBio shares are owned by company insiders. Comparatively, 18.2% of Ventyx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate ANAB or VTYX? AnaptysBio presently has a consensus price target of $42.38, suggesting a potential upside of 74.74%. Ventyx Biosciences has a consensus price target of $10.00, suggesting a potential upside of 380.77%. Given Ventyx Biosciences' higher possible upside, analysts plainly believe Ventyx Biosciences is more favorable than AnaptysBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AnaptysBio 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80Ventyx Biosciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media refer more to ANAB or VTYX? In the previous week, AnaptysBio had 4 more articles in the media than Ventyx Biosciences. MarketBeat recorded 4 mentions for AnaptysBio and 0 mentions for Ventyx Biosciences. AnaptysBio's average media sentiment score of 0.86 beat Ventyx Biosciences' score of 0.00 indicating that AnaptysBio is being referred to more favorably in the media. Company Overall Sentiment AnaptysBio Positive Ventyx Biosciences Neutral Is ANAB or VTYX more profitable? Ventyx Biosciences has a net margin of 0.00% compared to AnaptysBio's net margin of -125.70%. Ventyx Biosciences' return on equity of -47.45% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets AnaptysBio-125.70% -282.47% -30.79% Ventyx Biosciences N/A -47.45%-43.49% Which has better earnings & valuation, ANAB or VTYX? Ventyx Biosciences has lower revenue, but higher earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnaptysBio$91.28M7.81-$145.23M-$4.85-5.00Ventyx BiosciencesN/AN/A-$135.12M-$1.75-1.19 Which has more volatility & risk, ANAB or VTYX? AnaptysBio has a beta of -0.27, indicating that its share price is 127% less volatile than the S&P 500. Comparatively, Ventyx Biosciences has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. SummaryAnaptysBio and Ventyx Biosciences tied by winning 8 of the 16 factors compared between the two stocks. Get Ventyx Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for VTYX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTYX vs. The Competition Export to ExcelMetricVentyx BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$145.17M$2.87B$5.47B$8.95BDividend YieldN/A2.45%5.25%4.04%P/E Ratio-1.1920.8026.9920.11Price / SalesN/A286.31428.71119.81Price / CashN/A41.1936.8257.86Price / Book0.587.487.985.56Net Income-$135.12M-$55.04M$3.16B$248.40M7 Day Performance2.97%2.44%2.38%4.67%1 Month Performance-18.75%1.90%2.17%6.64%1 Year Performance-11.11%4.35%33.81%21.31% Ventyx Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTYXVentyx Biosciences2.3679 of 5 stars$2.08+2.0%$10.00+380.8%-9.2%$145.17MN/A-1.1930ANABAnaptysBio2.2778 of 5 stars$22.20-1.2%$42.38+90.9%-4.8%$660.18M$91.28M-4.58100IMTXImmatics2.4191 of 5 stars$5.38-0.9%$14.67+172.6%-52.6%$660.02M$168.65M-31.65260TRVITrevi Therapeutics3.1262 of 5 stars$5.47-2.7%$20.29+270.9%+115.4%$659.19MN/A-12.1620NUVBNuvation Bio3.4338 of 5 stars$1.96+1.3%$7.17+266.6%-34.3%$656.71M$7.87M-0.8360High Trading VolumeDAWNDay One Biopharmaceuticals1.7109 of 5 stars$6.50+0.5%$30.57+370.3%-55.3%$655.82M$131.16M-9.1560GHRSGH Research1.5694 of 5 stars$12.19-2.0%$32.00+162.5%+31.8%$647.23MN/A-15.4310STOKStoke Therapeutics3.9931 of 5 stars$11.35-2.4%$23.20+104.4%-7.2%$634.96M$190.91M14.37100SANASana Biotechnology2.5683 of 5 stars$2.73-2.8%$8.60+215.0%-23.4%$633.59MN/A-3.10380Gap UpMRVIMaravai LifeSciences3.727 of 5 stars$2.41-2.4%$6.64+175.5%-62.4%$629.01M$259.18M-2.11610URGNUrogen Pharma4.5452 of 5 stars$13.70+1.6%$32.86+139.8%-14.8%$621.99M$90.40M-4.31200Analyst Forecast Related Companies and Tools Related Companies AnaptysBio Competitors Immatics Competitors Trevi Therapeutics Competitors Nuvation Bio Competitors Day One Biopharmaceuticals Competitors GH Research Competitors Stoke Therapeutics Competitors Sana Biotechnology Competitors Maravai LifeSciences Competitors Urogen Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTYX) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ventyx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ventyx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
